[New treatments in movement disorders].

In recent years there have been considerable advances in the field of movement disorders which have decisively transformed not only the comprehension of the genetics and the pathophysiology of different diseases but have also improved the quality of life of these patients. Examples of these already available advances include the introduction of new treatments for previously untreatable diseases, such as botulinum toxin for dystonia, new therapeutic options or new forms of administration of levodopa for Parkinson disease, such as delayed levodopa, catecol-O-methyl transferase inhibitors and monotherapy with the classical and new dopaminergic agonists or new surgical techniques for previously unapproachable complications, such as dyskinesias in advanced Parkinson's disease. This study reviews the current treatment of Parkinson's disease, essential tremor, dystonia and different forms of choreas and indicates some of the experimental therapies which open renewed perspectives for neurodegenerative diseases, mainly Huntington's chorea and Parkinson's disease, such as the drugs with possible neuroprotective action, glutamatergic transmission reducers, neurotrophic factors and neuronal implants.